Cytokinetics, Inc.
Cytokinetics Reports Strong Q1 2026 Performance with MYQORZO Launch and Positive ACACIA-HCM Results
Summary
Cytokinetics, Incorporated reported its first quarter 2026 financial results, highlighting the successful U.S. launch of MYQORZO for symptomatic obstructive HCM, with over 275 healthcare providers prescribing the drug to an estimated 680 patients. The company also announced positive topline results from the ACACIA-HCM trial, demonstrating significant improvements in symptoms and exercise performance for patients with non-obstructive HCM. Total revenues for the quarter were $19.4 million, including $4.8 million from MYQORZO net product revenue. Despite the strong commercial momentum, the company reported a net loss of $206.0 million for the quarter.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement